Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?

SIMPLE SUMMARY: In oncology, a new era has emerged in the last ten years with the development of targeted and immune therapies. In hepatocellular carcinoma (HCC), several targeted agents (sorafenib, lenvatinib, cabozantinib, regorafenib, and ramucirumab) are approved and immunotherapy is now validat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancers (Basel)
Asıl Yazarlar: Boilève, Alice, Hilmi, Marc, Delaye, Matthieu, Tijeras-Raballand, Annemilaï, Neuzillet, Cindy
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2021
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8198554/
https://ncbi.nlm.nih.gov/pubmed/34070929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13112708
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller